Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Shunrong Ji

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5497-241X; OpenAlex author ID A5000579442. Sources: ClinicalTrials.gov.

Their work

Papers
60 (first author 6, last author 3)
Trials
1
Grants
0
Labs led
1
Collaborators
97
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 2 papers · 2015: 2 papers · 2016: 7 papers · 2017: 7 papers · 2018: 5 papers · 2019: 7 papers · 2020: 4 papers · 2021: 9 papers · 2022: 2 papers · 2023: 3 papers, 1 trial · 2024: 6 papers · 2025: 3 papers

Papers 50 of 60

  1. Acyl-CoA thioesterase 8 induces gemcitabine resistance via regulation of lipid metabolism and antiferroptotic activity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41401-025-01477-y↗
  2. Effect of Laparoscopic Versus Open Distal Pancreatectomy on Recurrence-free Survival in Patients With Left-sided Pancreatic Cancer: A Randomized Controlled Tri… Co-author DOI 10.1097/sla.0000000000006681↗
  3. The ACSS2-PPARD-BCAT1 axis synchronously regulates branched-chain amino acid metabolism and development in pancreatic cancer. Co-author DOI 10.3724/abbs.2025111↗
  4. NMI promotes tumor progression and gemcitabine resistance in pancreatic cancer via STAT3-IFIT3 axis. Co-author DOI 10.1002/mc.23645↗
  5. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.217197↗
  6. SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer. Co-author DOI 10.1038/s41401-023-01199-z↗
  7. Transcription factor EB reprograms branched-chain amino acid metabolism and promotes pancreatic cancer progression via transcriptional regulation of BCAT1. Co-author DOI 10.1111/cpr.13694↗
  8. Feasibility of laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a retrospective c… Co-author DOI 10.1186/s12957-023-03277-2↗
  9. Laparoscopic versus open pancreatoduodenectomy following neoadjuvant chemotherapy for borderline resectable pancreatic ductal adenocarcinoma: protocol of a mul… Co-author DOI 10.21203/rs.3.rs-3993645/v1↗
  10. Short-Term Outcomes Following Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.5210↗
  11. Hernandezine induces autophagic cell death in human pancreatic cancer cells via activation of the ROS/AMPK signaling pathway. Co-author DOI 10.1038/s41401-022-01006-1↗
  12. SETD8 inhibits ferroptosis in pancreatic cancer by inhibiting the expression of RRAD. Co-author DOI 10.1186/s12935-023-02899-6↗
  13. Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway. Co-author DOI 10.3389/fonc.2022.822039↗
  14. [Effect of laparoscopic surgery for pancreatic cancer after neoadjuvant chemotherapy]. Co-author DOI 10.3760/cma.j.cn112139-20210823-00389↗
  15. Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer. First author DOI 10.1002/ctm2.398↗
  16. Organoid model: A new hope for pancreatic cancer treatment? Last author DOI 10.1016/j.bbcan.2020.188466↗
  17. SETD8 potentiates constitutive ERK1/2 activation via epigenetically silencing DUSP10 expression in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.11.023↗
  18. FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. Last author DOI 10.1016/j.redox.2020.101807↗
  19. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications. Last author DOI 10.1038/s41401-020-00584-2↗
  20. FGFBP1-mediated crosstalk between fibroblasts and pancreatic cancer cells via FGF22/FGFR2 promotes invasion and metastasis of pancreatic cancer. Co-author DOI 10.1093/abbs/gmab074↗
  21. SETD8 induces stemness and epithelial-mesenchymal transition of pancreatic cancer cells by regulating ROR1 expression. Co-author DOI 10.1093/abbs/gmab140↗
  22. MTAP Deficiency-Induced Metabolic Reprogramming Creates a Vulnerability to Cotargeting De Novo Purine Synthesis and Glycolysis in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-20-0414↗
  23. ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells. Co-author DOI 10.1186/s12935-021-02210-5↗
  24. Oncogenic function of TRIM2 in pancreatic cancer by activating ROS-related NRF2/ITGB7/FAK axis. Co-author DOI 10.1038/s41388-020-01452-3↗
  25. Pin1 promotes pancreatic cancer progression and metastasis by activation of NF-κB-IL-18 feedback loop. Co-author DOI 10.1111/cpr.12816↗
  26. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. Co-author DOI 10.1136/gutjnl-2018-317163↗
  27. Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. Co-author PMID 32368394↗
  28. UHRF1 promotes aerobic glycolysis and proliferation via suppression of SIRT4 in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.03.024↗
  29. ABO Blood Group and the Risk of Pancreatic Neoplasms in Chinese Han Population: A Study at Shanghai Pancreatic Cancer Institute. First author DOI 10.1097/mpa.0000000000001408↗
  30. Homeodomain-interacting protein kinase 2 suppresses proliferation and aerobic glycolysis via ERK/cMyc axis in pancreatic cancer. Co-author DOI 10.1111/cpr.12603↗
  31. PIN1 Maintains Redox Balance via the c-Myc/NRF2 Axis to Counteract Kras-Induced Mitochondrial Respiratory Injury in Pancreatic Cancer Cells. Co-author DOI 10.1158/0008-5472.can-18-1968↗
  32. Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12935-019-0767-4↗
  33. PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis. Co-author DOI 10.1186/s12964-019-0344-4↗
  34. FGFBP1, a downstream target of the FBW7/c-Myc axis, promotes cell proliferation and migration in pancreatic cancer. Co-author PMID 31911852↗
  35. Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer? Co-author DOI 10.1007/s00018-017-2678-7↗
  36. Role of angiogenesis in pancreatic cancer biology and therapy. First author DOI 10.1016/j.biopha.2018.09.136↗
  37. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer. Co-author DOI 10.1038/onc.2017.393↗
  38. TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. Co-author DOI 10.1038/s41419-018-0367-6↗
  39. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. Co-author DOI 10.1111/cpr.12456↗
  40. ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.12.014↗
  41. Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going. Co-author DOI 10.1038/emm.2017.255↗
  42. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-16-0296↗
  43. Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.2147/ott.s145708↗
  44. A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. Co-author DOI 10.3892/ijo.2017.3938↗
  45. FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. Co-author DOI 10.3892/or.2017.5856↗
  46. Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.7150/jca.18901↗
  47. New insights into perineural invasion of pancreatic cancer: More than pain. Co-author DOI 10.1016/j.bbcan.2016.01.002↗
  48. Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbcan.2016.09.001↗
  49. ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.01.054↗
  50. Energy sources identify metabolic phenotypes in pancreatic cancer. Co-author DOI 10.1093/abbs/gmw097↗

Trials 1

  1. Long-term Prognosis for Non-functional Neuroendocrine Tumors of the Pancreatic Body and Tail ≤ 3cm Study director NCT05907824↗

Closest collaborators

The 25 strongest of 97 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 55 shared papers, 1 shared trial, 2012–2025 · strength 6.04
  2. Yi Qin · 48 shared papers, 2013–2025 · strength 4.53
  3. Xiaowu Xu · 26 shared papers, 2019–2025 · strength 3.60
  4. Wenyan Xu · 38 shared papers, 2012–2025 · strength 3.31
  5. Qifeng Zhuo · 17 shared papers, 2020–2025 · strength 2.46
  6. Wensheng Liu · 21 shared papers, 2017–2024 · strength 2.27
  7. Qiangsheng Hu · 23 shared papers, 2016–2023 · strength 2.07
  8. Ye Zeng · 14 shared papers, 2020–2025 · strength 2.06
  9. Jin Xu · 28 shared papers, 2013–2025 · strength 1.83
  10. Si Shi · 23 shared papers, 2014–2025 · strength 1.46
  11. Quanxing Ni · 24 shared papers, 2012–2019 · strength 1.44
  12. Zheng Zhang · 14 shared papers, 2018–2021 · strength 1.36
  13. Mengqi Liu · 10 shared papers, 2019–2024 · strength 1.11
  14. Chen Liang · 17 shared papers, 2016–2020 · strength 1.07
  15. Haidi Chen · 5 shared papers, 2021–2025 · strength 0.93
  16. Xiaowu Xu · 6 shared papers, 2019–2025 · strength 0.92
  17. Dingkong Liang · 16 shared papers, 2015–2018 · strength 0.92
  18. Qiqing Sun · 10 shared papers, 2018–2020 · strength 0.89
  19. Chenjie Zhou · 4 shared papers, 2024–2025 · strength 0.82
  20. Borui Li · 4 shared papers, 2024–2025 · strength 0.80
  21. Chen Liu · 12 shared papers, 2013–2025 · strength 0.75
  22. Haifeng Hu · 4 shared papers, 2021–2024 · strength 0.68
  23. Zheng Li · 4 shared papers, 2022–2025 · strength 0.67
  24. Jinfeng Xiang · 10 shared papers, 2016–2019 · strength 0.63
  25. Qingcai Meng · 8 shared papers, 2017–2020 · strength 0.59

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.